Ruvembri is under clinical development by Biophytis and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Pneumonia. According to GlobalData, Phase III drugs for Coronavirus Disease 2019 (COVID-19) Pneumonia have an 8% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Ruvembri’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ruvembri overview
BIO-101 (SARCONEOS) is under development for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19 pneumonia and COVID-19 induced respiratory failure, age-related sarcopenia including sarcopenic obesity, respiratory failure caused by the flu virus Influenza, Duchenne muscular dystrophy (DMD) and obesity. It is administered orally. The drug candidate is a phytoecdysone, which acts by targeting Mas-related G protein-coupled receptor, developed based on SARCOB platform.
It was also under development for the treatment of cachexia and spinal muscular atrophy.
Biophytis overview
Biophytis is a biotechnology company. The company develops drug candidates to treat age-related degenerative diseases that affects muscular and visual functions. It focuses on therapeutic solutions against age-related, impairing diseases. Biophytis product pipeline include Sarconeos (BIO101), a first-in-class drug candidate for the treatment of sarcopenic obesity and duchenne muscular dystrophy (DMD) and BIO103 to treat other muscle dystrophies; Macuneos (BIO201) and BIO203 peroxisome proliferator activated receptors (PPARs) to treat dry age-related macular degeneration (AMD) and other retinal diseases. The company develops drug candidates based on SARCOB and MACULIA technological platforms. Biophytis is headquartered in Paris, Ile-de-France, France.
For a complete picture of Ruvembri’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
